BioSpace

Cell therapy investment grows as safety events rankle Big Pharma's CAR T autoimmune push

Sail Biomedicine’s $925 million deal with Johnson & Johnson helped boost the cell and gene therapy sector over biologics in terms of venture capital fundraising in the third quarter.

By BioSpace

1 min read
Cell therapy investment grows as safety events rankle Big Pharma's CAR T autoimmune push
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights